In this webinar, Dr. Yoav Noam, Senior Manager R&D at Bio‑Techne, will discuss key analytical and practical considerations for evaluating next-generation biomarker platforms. Additionally, Dr. Noam will present data demonstrating femtogram level, precise detection of key blood‑based neurodegenerative biomarkers including NfL, GFAP, pTau217, and Amyloid β (aa1‑42), using the Simple Plex™ Ultra-Sensitive Assays on the Ella™ System, the next‑generation microfluidics‑based immunoassay platform.

The fully automated Ella system delivers reproducible quantification of low‑abundance biomarkers with minimal hands‑on time, enabling confident measurement in both serum and plasma even in healthy donors.

The Simple Plex ultra-sensitive technology combines advanced microfluidic engineering with optimized immunoassay chemistry to achieve exceptional sensitivity, precision, and throughput. Supporting both discovery and translational research workflows, the platform accelerates biomarker validation and advances research in neurodegenerative disease.